SoftBank Vision Fund 2 and RA Capital Management led a $140m Series C round in Ventus Therapeutics.

SoftBank Vision Fund 2 and RA Capital Management led a $140m Series C round in Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, with participation from Qatar Investment Authority, Andreessen Horowitz, BVF Partners, Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, Alexandria Venture Investments, GV and Versant Ventures. "We believe this funding from leading investors will help us scale up our ReSOLVE platform while simultaneously driving towards planned investigational new drug (IND) submissions for our three lead programs in 2023," Marcelo Bigal, Ventus President and CEO.